Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 155

Results For "CAS"

1927 News Found

DCGI approves Themis Medicare's Viralex for Covid-19 treatment
News | March 03, 2022

DCGI approves Themis Medicare's Viralex for Covid-19 treatment

Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections


Diversification by pharma companies critical to repositioning supply chain
News | March 02, 2022

Diversification by pharma companies critical to repositioning supply chain

Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel


SeQuent Scientific completes acquisition of Nourrie in Brazil
News | March 02, 2022

SeQuent Scientific completes acquisition of Nourrie in Brazil

Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%


Trivitron Healthcare acquires U.S. based The Kennedy Company
Clinical Trials | March 02, 2022

Trivitron Healthcare acquires U.S. based The Kennedy Company

This has further strengthened its manufacturing presence in the United States of America


Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period
Biotech | March 01, 2022

Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period

High level of vaccine efficacy maintained over a 6-month period of surveillance


Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion
News | February 28, 2022

Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion

BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets


BDR Pharma launches enzalutamide in 160 mg strength
Biotech | February 28, 2022

BDR Pharma launches enzalutamide in 160 mg strength

This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage


Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr
News | February 28, 2022

Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr

Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business


Jeffrey DeAlmeida appointed Senior VP of BASF pharma solutions
People | February 28, 2022

Jeffrey DeAlmeida appointed Senior VP of BASF pharma solutions

In this role, Jeffrey DeAlmeida takes responsibility for BASF’s global pharmaceutical solutions portfolio and the Nutrition & Health business in North and South America


Japan approves Keytruda plus Lenvima for two types of cancer
Drug Approval | February 26, 2022

Japan approves Keytruda plus Lenvima for two types of cancer

Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.